James Edgemond Sells 10,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction on Monday, April 13th. The shares were sold at an average price of $574.88, for a total value of $5,748,800.00. Following the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at $10,851,434.88. This represents a 34.63% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

James Edgemond also recently made the following trade(s):

• On Thursday, April 9th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $577.89, for a total value of $5,778,900.00.
• On Monday, April 6th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $558.40, for a total value of $5,584,000.00.
• On Thursday, April 2nd, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $561.50, for a total value of $5,615,000.00.
• On Monday, March 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $593.17, for a total value of $5,931,700.00.
• On Thursday, March 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $535.90, for a total value of $5,359,000.00.
• On Monday, March 23rd, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $527.48, for a total value of $5,274,800.00.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $577.58 on Thursday. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $607.89. The firm has a market cap of $25.32 billion, a price-to-earnings ratio of 20.70, a PEG ratio of 1.65 and a beta of 0.75. The business’s fifty day moving average is $522.64 and its 200 day moving average is $487.71.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The company had revenue of $790.20 million for the quarter, compared to analyst estimates of $814.80 million. During the same period in the previous year, the company posted $6.19 EPS. The firm’s revenue for the quarter was up 7.4% compared to the same quarter last year. Equities analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently issued reports on UTHR shares. Wells Fargo & Company boosted their price objective on United Therapeutics from $486.00 to $575.00 and gave the company an “equal weight” rating in a research note on Tuesday, March 31st. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. UBS Group boosted their price objective on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Bank of America boosted their price objective on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research note on Tuesday, March 31st. Finally, HC Wainwright upped their target price on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Ten investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and an average target price of $601.50.

Hedge Funds Weigh In On United Therapeutics

A number of institutional investors have recently added to or reduced their stakes in UTHR. Wellington Management Group LLP increased its stake in United Therapeutics by 74.5% in the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after acquiring an additional 1,042,711 shares during the last quarter. Darwin Global Management Ltd. bought a new position in shares of United Therapeutics during the 3rd quarter valued at about $317,617,000. Norges Bank bought a new position in shares of United Therapeutics during the 4th quarter valued at about $293,418,000. Avoro Capital Advisors LLC increased its position in shares of United Therapeutics by 17.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after purchasing an additional 383,838 shares during the last quarter. Finally, Janus Henderson Group PLC increased its position in shares of United Therapeutics by 75.1% during the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock valued at $387,801,000 after purchasing an additional 341,383 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.